61 results on '"Langemeijer, Saskia"'
Search Results
2. Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria
3. MDS-273 Oral Iptacopan Monotherapy Increases Paroxysmal Nocturnal Hemoglobinuria (PNH) Red Blood Cell Clone Size Via Control of Intra- and Extravascular Hemolysis in Anti-C5-Treated PNH Patients With Anemia
4. POSTER: MDS-273 Oral Iptacopan Monotherapy Increases Paroxysmal Nocturnal Hemoglobinuria (PNH) Red Blood Cell Clone Size Via Control of Intra- and Extravascular Hemolysis in Anti-C5-Treated PNH Patients With Anemia
5. PB2059: SENSITIVITY AND SUBGROUP ANALYSES FURTHER SUPPORT CLINICAL SIMILARITY IN EFFICACY BETWEEN ABP 959 AND ECULIZUMAB REFERENCE PRODUCT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
6. P494: A FIRST-IN-HUMAN STUDY OF CD123 NK CELL ENGAGER SAR443579 IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA OR HIGH RISK-MYELODYSPLASIA
7. S182: ORAL IPTACOPAN MONOTHERAPY INCREASES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) RED BLOOD CELL CLONE SIZE VIA CONTROL OF INTRA- AND EXTRAVASCULAR HEMOLYSIS IN ANTI-C5-TREATED PNH PATIENTS WITH ANEMIA
8. P731: SURVIVAL IN LOWER-RISK MDS PATIENTS FROM EUMDS REGISTRY BY TWO TRANSPLANT SELECTION CRITERIA - IMPLICATIONS FOR TRANSPLANT DECISION
9. Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study
10. Ravulizumab is a suitable long-term treatment option for patients with paroxysmal nocturnal hemoglobinuria
11. Effect of Eculizumab on Iron Metabolism in Transfusion-independent Patients With Paroxysmal Nocturnal Hemoglobinuria
12. Proteinuria and Exposure to Eculizumab in Atypical Hemolytic Uremic Syndrome
13. Raising the standards of patient‐centered outcomes research in myelodysplastic syndromes: Clinical utility and validation of the subscales of the QUALMS from the MDS‐RIGHT project
14. Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III Apply-PNH Study
15. Dose optimalization of subcutaneous ravulizumab is predicted to yield significant savings and to improve patient friendliness
16. Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry: A Report on 197 Cases
17. Efficacy and Safety of Biosimilar Candidate ABP 959 As Compared with Eculizumab Reference Product in Paroxysmal Nocturnal Hemoglobinuria
18. Validation of the Qualms Questionnaire to Assess Health-Related Quality of Life in European and Israeli Patients with Myelodysplastic Syndromes: Results from the MDS-Right Project
19. Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry, a Unique Prospective Real-World Dataset
20. Genetic Diversity within Leukemia-Associated Immunophenotype-Defined Subclones in AML
21. Anti Thymocyte Globulin-Based Treatment for Acquired Bone Marrow Failure in Adults
22. Infections during eculizumab therapy in a Dutch population of patients with paroxysmal nocturnal haemoglobinuria
23. A predictive algorithm using clinical and laboratory parameters may assist in ruling out and in diagnosing MDS
24. A phase I clinical trial to study the safety of treatment with tipifarnib combined with bortezomib in patients with advanced stages of myelodysplastic syndrome and oligoblastic acute myeloid leukemia
25. The potential of individualized dosing of ravulizumab to improve patient‐friendliness of paroxysmal nocturnal haemoglobinuria treatment at reduced costs
26. Neutrophil specific granule and NETosis defects in gray platelet syndrome
27. One‐year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab
28. Placental disposition of eculizumab, C5 and C5‐eculizumab in two pregnancies of a woman with paroxysmal nocturnal haemoglobinuria
29. Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective
30. Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria
31. Eculizumab impairs Neisseria meningitidis serogroup B killing in whole blood despite 4CMenB vaccination of PNH patients
32. Successful treatment of a PNH patient non‐responsive to eculizumab with the novel complement C5 inhibitor coversin (nomacopan)
33. Prophylactic Antibiotic Use and Risk of Meningococcal Infections in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Eculizumab Who Received Meningococcal Vaccination: Results from the International PNH Registry
34. One-Year Efficacy and Safety from a Phase 3 Trial of Ravulizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Prior Eculizumab Treatment
35. Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab
36. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: the 302 study
37. Excess Mortality in Low-Risk MDS Can be Explained By MDS and AML Related Causes of Death
38. MDS Diagnosis: Many Patients May Not Require Bone Marrow Examination
39. Longitudinal Changes of Impairments in Health-Related Quality of Life in Lower-Risk MDS Patients: A European Leukemianet Study
40. Current Status and Optimal Management of Eculizumab Poor-Responders Due to C5 Polymorphisms
41. Results from a Phase 3, Multicenter, Non-Inferiority Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Eculizumab
42. Elevated Labile Plasma Iron (LPI) Levels in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Are Associated with Decreased Quality of Life and Reduced Survival
43. Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes
44. Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS
45. Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study
46. Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes
47. Impact of Treatment with Iron Chelators in Lower-Risk MDS Patients Participating in the European Leukemianet MDS (EUMDS) Registry
48. Elevated Labile Plasma Iron Levels (LPI) and Increased Oxidative Stress Are Associated with Red Blood Cell Transfusions in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Subtitle: from the European Leukemianet MDS Registry
49. Apoptosis-Related Gene Expression Profiling in Hematopoietic Cell Fractions of MDS Patients
50. Coversin is effective in the treatment of PNH with resistance to eculizumab due to complement C5 polymorphism
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.